What’s new

• The Q4 FY26 earnings call transcript for the May 26, 2026 call has been filed.
• Core financial results and management commentary were already disclosed in the live concall summary filed the same day.
• Key themes from the call, including clinic losses, UK acquisition impact, and capex miss, were covered in the original summary.

Why it matters

Transcript filings are a procedural disclosure. This one confirms no new information was held back from the initial summary. The market's picture of Narayana's quarter is unchanged.

What we’re watching

• Management's next update on integrating the UK acquisition.
• Whether the capex miss leads to revised investment guidance.
• Profitability trends at the clinic level in the next quarterly results.

The full read

Narayana Hrudayalaya's Q4 FY26 call happened on May 26. The live summary was filed the same day. Today's filing is the full transcript. It provides the verbatim record, but no new figure, forecast, or strategic shift. The market already had the key data: clinic losses, the UK acquisition's impact, and the capex miss. This is an archival filing. Hardly a catalyst. The content is identical to what traders processed two weeks ago.

Primary source: BSE · NSE

What’s new

• Clinic and insurance losses stayed flat at ₹66 cr for FY26, contradicting management guidance that they were declining.
• The UK acquisition is diluting consolidated PAT and return on equity, reversing prior EPS-neutral assurances.
• Capex was just ₹109 cr against a ₹424 cr budget; northern cluster expansion plans are scrapped.

Why it matters

Narayana's May concall is a litany of reversed guidance. Management had told investors clinic losses were narrowing, the UK deal wouldn't dilute earnings, and northern expansion was on track. None of those are now true. The India hospital EBITDA margin did expand 360 basis points to 25.1%, which is real progress. But the credibility gap between what was promised and what was delivered is the story here.

What we’re watching

• Whether the UK deal will eventually deliver the promised EPS neutrality or remain a drag.
• If the unspent capex is redeployed or signals a structural shift in expansion strategy.
• How quickly clinic losses can actually be reduced now that the flat trajectory is acknowledged.

The full read

Narayana Hrudayalaya's May concall read like a mea culpa. Management admitted clinic losses stayed flat at ₹66 crore for FY26, reversing earlier guidance that they were falling. The UK acquisition is now actively diluting consolidated PAT and return on equity, a direct contradiction of the prior assurance that the deal would be earnings-per-share neutral. Northern cluster expansion is off the table entirely, with the company pivoting to south and east India. The capex miss was staggering: ₹109 crore spent against a ₹424 crore budget, a 74% shortfall management blamed on elections and labor shortages. The India hospital EBITDA margin did expand 360 basis points to 25.1%, driven by case complexity and payer mix. That's real operational progress. But it's overshadowed by the fact that three separate management assurances proved wrong in the same quarter. The credibility gap is now the primary overhang.

Primary source: BSE · NSE

What’s new

• Board formalizes FY26 results already disclosed to the market.
• Company authorized to raise up to ₹1,500 cr in fresh debt.
• Final dividend fixed at ₹4.50 per share, consistent with the prior year.

Why it matters

The filing is purely procedural, confirming numbers the market has already digested. The authorization for debt issuance provides necessary liquidity headroom without creating immediate operational surprises.

What we’re watching

• Deployment plans for the ₹1,500 cr debt issuance.
• Integration progress of the UK acquisition following the 44% revenue surge.
• Updates on margin profiles as the new assets scale.

The full read

Narayana Hrudayalaya’s latest board filing is a procedural wrap on its FY26 financial cycle. It adds nothing new.

With standalone revenue up 10.7% to ₹39,751 million and consolidated revenue surging 44% following the UK acquisition, the numbers were already public knowledge before this meeting. The board simply finalized the audit process and re-appointed an independent director.

Beyond these routine items, management secured authorization to raise up to ₹1,500 crore in fresh debt, a move that provides the company with significant balance-sheet flexibility to manage its expanded footprint. The dividend remains unchanged at ₹4.50 per share. This is a housekeeping outcome that confirms the current path without deviating from guidance or prior reports, keeping the focus squarely on the integration of its recent international expansion. Stability is the message here.

Primary source: BSE · NSE

What’s new

• Narayana Hrudayalaya released its official Q4 and FY26 press summary.
• The data matches prior disclosures and incorporates the recent UK acquisition.
• No new financial information was provided beyond previously reported results.

Why it matters

The market has already absorbed these figures, as the numbers align with earlier board meeting outcomes. This is a procedural update rather than a new market catalyst.

What we’re watching

• Future margin trends as the UK operations integrate.
• Updates on capacity expansion plans.
• Any shift in management outlook during the upcoming concall.

The full read

Narayana Hrudayalaya has released its press summary for Q4 FY26 and the full fiscal year. The results show consolidated revenue growth of 75.8% year-on-year for the quarter and 44% for the full year.

No surprises here.

Investors should understand that these figures were fully captured in prior board outcome disclosures and annual regulatory filings, meaning the recent UK acquisition impact was already priced in by the broader market. Since the press release is essentially a procedural wrap-up of previously confirmed events, it offers nothing new to change the investment thesis, leaving current operational performance and the upcoming integration success as the only variables that matter.

Primary source: BSE · NSE

What’s new

• Consolidated revenue grew 44% to ₹78,960 million, driven by the UK's Practice Plus Group acquisition.
• Standalone net profit climbed 16.7% to ₹5,031 million on revenue of ₹39,751 million.
• Board sought enabling approval to issue up to ₹1,500 crore in debt.

Why it matters

The jump in consolidated figures masks the stability of the domestic business. With domestic growth in the low double digits and a steady dividend, the company is prioritizing balance sheet flexibility through its new ₹1,500 crore debt ceiling.

What we’re watching

• Margin contribution from the UK business in the upcoming quarters.
• Actual utilization of the newly approved ₹1,500 crore debt facility.
• Whether domestic growth accelerates from the current 10.7% level.

The full read

Narayana Hrudayalaya closed FY26 with a performance defined by its offshore expansion. Consolidated revenue grew 44% to ₹78,960 million, a spike directly tied to the November 2025 integration of the UK-based Practice Plus Group. Standalone operations, by contrast, grew 10.7% to ₹39,751 million, with net profit rising 16.7% to ₹5,031 million. The board kept the final dividend at ₹4.50 per share and secured enabling authority to raise up to ₹1,500 crore in debt. These results contain no surprises. The numbers align with market expectations, reflecting a business that is growing in scale while maintaining its core domestic profitability. The focus now shifts from integration to whether the UK assets generate the returns necessary to justify the company's planned debt capacity.

Primary source: BSE · NSE

What’s new

• Consolidated revenue rose 44% YoY to ₹78,960 million.
• Standalone net profit hit ₹5,031 million, a 16.7% increase.
• Board approved a final dividend of ₹4.50 per share and debt issuance up to ₹1,500 crores.

Why it matters

The consolidated top-line surge reflects the integration of Practice Plus Group, Narayana’s major UK expansion. Routine dividends and debt approvals signal stability, leaving the focus on the company's ability to maintain standalone margins while managing its new international footprint.

What we’re watching

• Margin progression as the UK hospitals are fully integrated into the consolidated P&L.
• Usage of the newly approved ₹1,500 crore debt headroom.
• Standalone core growth trends in the coming fiscal year.

The full read

Narayana Hrudayalaya closed FY26 with a 44% surge in consolidated revenue to ₹78,960 million. This sharp jump is the result of the Practice Plus Group acquisition completed in November 2025. Standalone performance was more measured, with revenue climbing 10.7% to ₹39,751 million and net profit growing 16.7% to ₹5,031 million. The board kept the final dividend unchanged at ₹4.50 per share and authorised the company to raise up to ₹1,500 crores in debt. These results contain no surprises. The numbers align with broad expectations, confirming that the company's recent international expansion is the primary driver of its current scale. What changes from here is the company's ability to manage its new debt headroom and sustain standalone profitability while balancing its growing UK-based operations.

Primary source: BSE · NSE

What’s new

• Standalone annual profit grew 16.7% while revenue rose 10.7% year-on-year.
• The board recommended a final dividend of ₹4.50 per share.
• Directors approved a new debt-raising limit of ₹1,500 crore.

Why it matters

The performance tracks the company’s existing growth path. These figures offer no surprises, confirming that operations continue as expected.

What we’re watching

• Deployment plans for the newly approved ₹1,500 crore debt facility.
• Commentary on margin sustainability in upcoming investor calls.
• Dividend payout consistency for future years.

The full read

Narayana Hrudayalaya delivered 10.7% revenue growth and a 16.7% increase in net profit for the year ending March 31, 2026. These audited figures meet market expectations. The company also declared a final dividend of ₹4.50 per share and cleared the path to borrow up to ₹1,500 crore through a new debt-issuance resolution. The results show a steady growth trajectory. The next test is how management uses the newly approved debt headroom for expansion.

Primary source: BSE · NSE